Presenter: Kylee Maxfield
Authors: Kylee Maxfield, Stephen Chamberland
Faculty Advisor: Stephen Chamberland
Institution: Utah Valley University
Since their isolation in 2008-2009, the marine bioorganic molecules known as the clavatadines have been considered as promising frameworks for potential pharmaceutical applications. Both clavatadine A and B have shown to be strong and selective inhibitors of human blood coagulation factor XIa (FXIa). Analogs of clavatadine C have also shown to have moderate cytotoxicity against multiple cancer cell lines and are being explored as possible anticancer agents. To date, complete syntheses of only clavatadine A, B, and C have been published and thus the biological activity of clavatadine D and E have not yet been explored. We have completed the first total synthesis of clavatadine D and have also completed the second total synthesis of clavatadine C due to their structural similarities. Our convergent synthetic approach has allowed us to complete these syntheses in only five steps and can be readily applied to the preparation of numerous analogs of both molecules. With the first total synthesis of clavatadine D complete, possible biological applications may be explored and initial bioactivity findings will be presented.